Adrenomedullin disrupts insulin signaling in blood vessels, leading to systemic insulin resistance in obesity-associated type 2 diabetes.

JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...

With Robert F. Kennedy Jr nearing confirmation as US health secretary, Australian scientists are already feeling the effects ...

Noticing excess thinning or shedding of your hair? Us too—we tried hair growth oils and serums for six weeks to find the ones that made a noticeable difference.

Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts.

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.